Page 5 - Roche Diagnostics News Today

#industry #news #UK #2024 #insights #zenopa #recruitment #Zimmer and #NuVasive Join #MedAccred #Platform #medical #device #accreditation #manufacturing #consensus

Check out Money FM's best weekly podcasts. Read more at straitstimes.com.

<p>The Global Alzheimer’s Platform Foundation<em><sup>®</sup></em>, (GAP) is releasing the first results from the Bio-Hermes-001 Study. This study in over 1000 community-based participants from throughout the US compared the results of blood and digital biomarkers with brain amyloid PET scans or cerebrospinal fluid assays. The study<em> </em>revealed a strong correlation between several blood tests, particularly p-tau 217, with the pres...

The Global Alzheimer's Platform Foundation, (GAP) is releasing the first results from the Bio-Hermes-001 Study.

For patients with recent cryptogenic stroke and evidence of atrial cardiopathy, the risk for recurrent stroke is not reduced with apixaban.

20 February 20, 2024Announcement no. 02 Roche Diagnostics and BioPorto expand collaboration COPENHAGEN, DENMARK and BOSTON, MA, 20 February, 2024, – BioPorto A/S , has today announced an...

Danish company BioPorto announced on Tuesday that it was extending its strategic collaboration with Roche Diagnostics, Roches in vitro diagnostics subsidiary.BioPorto, whose test for the biomarker of...

No significant difference noted in recurrent stroke, symptomatic intracranial hemorrhage for patients receiving apixaban, aspirin.

UK patients want better access to early and accurate diagnosis of health problems, according to new survey data from the Patients Association.

More than 415,000 people had been waiting longer than the six week target for a key diagnostic check in December, according to NHS England data.